The results and conclusions of the work conducted by the Lymphoma Research Experts ecosystem are published in leading medical journals.
Lysa
2022_LYSA_Genomic profiling for clinical decision making in lymphoid neoplasms
DOI: 10.1182/blood.2022015854
Learn more
Lysa
2022_LYSA_Transplant-ineligible but chimeric antigen receptor T-cells eligible: a real and relevant population
DOI: 10.1016/j.ejca.2022.08.019
Learn more
Lysa
2022_LYSA_Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine-treated, interimPET-negative classical Hodgkin Lymphoma patients: A radio-genomic study
DOI: 10.1002/hon.3025
Learn more
Lysa
2022_LYSA_Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paper
DOI: 10.1002/hon.3013
Learn more
Lysa
2022_LYSA_Prognostic value of FDG‐PET/CT response for patient selection before chimeric antigen receptor‐T‐cells therapy in non‐Hodgkin lymphoma
DOI: 10.1002/hon.2965
Learn more
Lysa
2022_LYSA_Clinical presentation, outcome, and prognostic markers in patients with intravascular large B-cell lymphoma, a lymphoma study association (LYSA) retrospective study
DOI: 10.1002/cam4.4742
Learn more
Lysa
2022_LYSA_Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV
DOI: 10.1182/bloodadvances.2022008355
Learn more
Lysa
2022_LYSA_The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
DOI: 10.1182/blood.2022015851
Learn more
Lysa
2022_LYSA_Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma
DOI: 10.1182/bloodadvances.2022007371
Learn more
Lysa
2022_LYSA_Humoral immune depression following autologous stem cell transplantation is a marker of prolonged response duration in patients with mantle cell lymphoma
DOI: 10.3324/haematol.2021.279561
Learn more
Lysa
2022_LYSA_The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
DOI: 10.1038/s41375-022-01620-2
Learn more
Lysa
2022_LYSA_End of induction positron emission tomography complete response (PET-CR) as a surrogate for progression-free survival in previously untreated follicular lymphoma
DOI: 10.1111/bjh.18217
Learn more
Lysa
2022_LYSA_Systematic review reveals urgent need to homogenize endpoints choices and definitions in marginal zone lymphomas trials
DOI: 10.1080/10428194.2022.2032038
Learn more
Lysa
2022_LYSA_Chemotherapy-free treatment in unfit patients aged 75 years and older with DLBCL: toward a new paradigm?
DOI: 10.1016/S2666-7568(22)00150-7
Learn more
Lysa
2022_LYSA_Peripheral T-Cell Lymphomas: Therapeutic Approaches
DOI: 10.3390/cancers14092332
Learn more
Lysa
2022_LYSA_The EHA Research Roadmap: Malignant Lymphoid Diseases
DOI: 10.1097/HS9.0000000000000726
Learn more
Lysa
2022_LYSA_Novel T Follicular Helper-like T-Cell Lymphoma Therapies: From Preclinical Evaluation to Clinical Reality
DOI: 10.3390/cancers14102392
Learn more
Lysa
2022_LYSA_Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients
DOI: 10.1182/blood.2021014506
Learn more
Lysa
2022_LYSA_The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target‑Mediated Drug Disposition
DOI: 10.1007/s40262-021-01081-3
Learn more
Lysa
2022_LYSA_Chapter 22: Bridging Chemotherapy: Relapsed/Refractory Aggressive B-Cell Lymphoma
DOI: 10.1007/978-3-030-94353-0_22
Learn more
Lysa
2022_LYSA_Azacytidine and Venetoclax in Relapsed and Refractory Patients With Angioimmunoblastic T-cell Lymphoma
DOI: 10.1097/HS9.0000000000000675
Learn more
Lysa
2022_LYSA_What Prognostic Markers Should Be Evaluated in Marginal Zone Lymphoma? A Survey Among Leading International Experts
DOI: 10.1097/HS9.0000000000000680
Learn more
Lysa
2022_LYSA_PET imaging: back in the game for gastric EMZL?
doi: 10.1182/blood.2021013964.
Learn more